Abstract
Gastrointestinal cancers refer to a group of deadly malignancies of the gastrointestinal tract and organs of the digestive system. Over the past decades, considerable amounts of medicinal plants have exhibited potent anticancer effects on different types of gastrointestinal cancers. OMICS, systems biology approaches covering genomics, transcriptomics, proteomics and metabolomics, are broadly applied to comprehensively reflect the molecular profiles in mechanistic studies of medicinal plants. Single- and multi-OMICS approaches facilitate the unravelling of signalling interaction networks and key molecular targets of medicinal plants with anti-gastrointestinal cancer potential. Hence, this review summarizes the applications of various OMICS and advanced bioinformatics approaches in examining therapeutic targets, signalling pathways, and the tumour microenvironment in response to anticancer medicinal plants. Advances and prospects in this field are also discussed.
Highlights
Gastrointestinal cancers (GI cancers), mainly colorectal, gastric, hepatocellular, pancreatic and oesophageal cancers, contribute to high cancer-related mortality worldwide with significant morbidity and poor prognosis (Kuntz et al, 2021)
This review focused on the current OMICS technologies utilized for understanding the actions of anticancer medicinal plants in the treatment of GI cancer (Figure 1)
A proteomics study based on dimethyl labelling combined with nano-LC–mass spectrometry (MS)/MS revealed that the cellular response to Carnosic acid (CA) induced ER stress, and CS treatment directly inhibited 20S proteasome catalytic activity in HT-29 cells, suggesting that
Summary
Gastrointestinal cancers (GI cancers), mainly colorectal, gastric, hepatocellular, pancreatic and oesophageal cancers, contribute to high cancer-related mortality worldwide with significant morbidity and poor prognosis (Kuntz et al, 2021). GI cancer patients benefit from medicinal plants as anticancer adjuvants in therapeutic effect enhancement, adverse reaction reduction, immune function improvement and drug resistance elimination (Hu et al, 2016). This review focused on the current OMICS technologies utilized for understanding the actions of anticancer medicinal plants in the treatment of GI cancer (Figure 1). The applications of OMICS have merit in identifying antiCRC active compounds from medicinal plants and helping to unravel underlying anticancer mechanisms, including regulation of apoptosis, anticancer stress, and the host immune response (Table 1). Incorporating a mass spectrometry-based label-free shotgun proteomics approach and proteome profiler antibody arrays characterized novel proteomic signatures and identified significant protein expression differences between GS-treated and untreated HCT116 cells, including p53, TRIAL, TNF-α/NF-kB, and apoptosis-related proteins. A proteomics study based on dimethyl labelling combined with nano-LC–MS/MS revealed that the cellular response to CA induced ER stress, and CS treatment directly inhibited 20S proteasome catalytic activity in HT-29 cells, suggesting that
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
